Zhi-Wei Yang1,2†, Yi-Zhen Zhao1†, Yong-Jian Zang1, He Wang1, Xun Zhu1, Ling-Jie Meng1, Xiao-Hui Yuan3, Lei Zhang1**, Sheng-Li Zhang1**
1MOE Key Laboratory for Nonequilibrium Synthesis and Modulation of Condensed Matter, School of Science, Xi'an Jiaotong University, Xi'an 710049 2School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049 3Institute of Biomedicine, Jinan University, Guangzhou 510632
Abstract：Coronavirus Disease 2019 (COVID-19), caused by the novel coronavirus, has spread rapidly across China. Consequently, there is an urgent need to sort and develop novel agents for the prevention and treatment of viral infections. A rapid structure-based virtual screening is used for the evaluation of current commercial drugs, with structures of human angiotensin converting enzyme II (ACE2), and viral main protease, spike, envelope, membrane and nucleocapsid proteins. Our results reveal that the reported drugs Arbidol, Chloroquine and Remdesivir may hinder the entry and release of virions through the bindings with ACE2, spike and envelope proteins. Due to the similar binding patterns, NHC ($\beta$-d-N4-hydroxycytidine) and Triazavirin are also in prospects for clinical use. Main protease (3CLpro) is likely to be a feasible target of drug design. The screening results to target 3CLpro reveal that Mitoguazone, Metformin, Biguanide Hydrochloride, Gallic acid, Caffeic acid, Sulfaguanidine and Acetylcysteine seem be possible inhibitors and have potential application in the clinical therapy of COVID-19.
Sheahan T P, Sims A C, Leist S R, Schäfer A, Won J, Brown A J, Montgomery S A, Hogg A, Babusis D, Clarke M O, Spahn J E, Bauer L, Sellers S, Porter D, Feng J Y, Cihlar T, Jordan R, Denison M R and Baric R S 2020 Nat. Commun.11 222
[3]
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J A, Yu T, Zhang X and Zhang L 2020 Lancet395 507
[4]
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung K S M, Lau E H Y, Wong J Y, Xing X, Xiang N, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Li M, Tu W, Chen C, Jin L, Yang R, Wang Q, Zhou S, Wang R, Liu H, Luo Y, Liu Y, Shao G, Li H, Tao Z, Yang Y, Deng Z, Liu B, Ma Z, Zhang Y, Shi G, Lam T T Y, Wu J T K, Gao G F, Cowling B J, Yang B, Leung G M and Feng Z 2020 New Engl. J. Med. (in press)
Holshue M L, DeBolt C, Lindquist S, Lofy K H, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber S I, Kim L, Tong S, Lu X, Lindstrom S, Pallansch M A, Weldon W C, Biggs H M, Uyeki T M, Pillai S K and Washington State -nCo V C I T 2020 New Engl. J. Med. (in press)
[7]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J and Cao B 2020 Lancet395 497
[8]
Zhou P, Yang X L, Wang X G, Hu B, Zhang L, Zhang W, Si H R, Zhu Y, Li B, Huang C L, Chen H D, Chen J, Luo Y, Guo H, Jiang R D, Liu M Q, Chen Y, Shen X R, Wang X, Zheng X S, Zhao K, Chen Q J, Deng F, Liu L L, Yan B, Zhan F X, Wang Y Y, Xiao G F and Shi Z L 2020 Nature579 270
[9]
Wu F, Zhao S, Yu B, Chen Y M, Wang W, Song Z G, Hu Y, Tao Z W, Tian J H, Pei Y Y, Yuan M L, Zhang Y L, Dai F H, Liu Y, Wang Q M, Zheng J J, Xu L, Holmes E C and Zhang Y Z 2020 Nature579 265
[10]
Wrapp D, Wang N, Corbett K S, Goldsmith J A, Hsieh C L, Abiona O, Graham B S and McLellan J S 2020 Science367 1260
Xia J W, Yang L, Dong L, Niu M J, Zhang S L, Yang Z W, Wumaier G, Li Y, Wei X M, Gong Y, Zhu N and Li S Q 2018 Front. Pharmacol.9 134
[15]
Towler P, Staker B, Prasad S G, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales N A, Patane M A and Pantoliano M W 2004 J. Biol. Chem.279 17996
2020, Vol. 37 
